Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.33 |
| ▸ | PGR | P06401 | 4/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560541 | 0.84 | HTR2C (0.36) | GRM2ALDH1A1KDM4ECYP1A2GLA | |
| SCHEMBL5975117 | 0.84 | NR3C1 (0.41) | GRM2NR3C1PGRNR3C2ALDH1A1 | |
| SCHEMBL6561713 | 0.78 | ALDH1A1 (0.48) | ALDH1A1NPSR1 | |
| SCHEMBL1400685 | 0.76 | PPARD (0.37) | ALDH1A1KDM4ECYP1A2GLACYP3A4 | |
| SCHEMBL6559556 | 0.69 | KCNH2 (0.43) | CYP2C9 | |
| SCHEMBL1760417 | 0.67 | CNR1 (0.50) | ALDH1A1KDM4ECYP3A4HPGDNPSR1 | |
| SCHEMBL30027246 | 0.67 | CNR1 (0.50) | ALDH1A1KDM4ECYP3A4HPGDNPSR1 | |
| SCHEMBL6561562 | 0.66 | PLA2G2A (0.37) | ALDH1A1KDM4ECYP3A4HPGDHTR2C | |
| SCHEMBL23397300 | 0.65 | HTR2C (0.37) | NR3C1PGRNR3C2HTR2C | |
| SCHEMBL2457616 | 0.63 | ALDH1A1 (0.38) | ALDH1A1KDM4ECYP1A2CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006091496-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-0948327-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-0948327-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6515015-B1 | In combination with one or more known sulfonylureas, biguanides, alpha -glucosidase inhibitors, other insulin secretogogues or insulin | MERCK & CO. INC. | 2003-02-04 | — | — | US | disclosed |
| US-6160000-A | Antidiabetic agents based on aryl and heteroarylacetic acids | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6090839-A | REDUCING TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0948327-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027974-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | GRM2 1/4885NR3C1 276/4885PGR 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.